{"ticker": {"uuid": "53fda142-3b57-49c0-a6be-af2bdbd78b33", "symbol": "DERM", "name": "Journey Medical Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors", "summary": "Wasatch Advisors has increased its beneficial ownership in Journey Medical Corp (DERM) to 13.3%, holding 2,858,930 shares. This information was disclosed in an Amendment No. 3 to a Schedule 13G filing. Wasatch Advisors maintains sole voting power over 2,664,647 shares and sole di", "url": "https://www.stocktitan.net/sec-filings/DERM/schedule-13g-a-journey-medical-corp-amended-passive-investment-disclo-f5e09ec5230d.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:09:30", "published_display": "15 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Journey Medical Corporation \u2013 NASDAQ:DERM", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOWmlMOW14NHpUb0hBUVZfNUF0ajk1c3IzX3hsSVFib19UUDI4dVVBMlRROVdDcnR0UER3aUp5YzdkaWI2VmZUWWFsSFF0VDhJeUVMek5tenJjYS1UR0NtVXJMOUNIN1JGLXhRLXhGMkYxV2cxTXlkeDVjSHpYeUFtUjl4S1JmSWJlM1Q5MDYtaUp1dXVfUFB3amNZVkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T10:04:01+00:00", "published_display": "12 Jul 2026 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of \"Hold\" from Analysts", "summary": "Journey Medical Corporation (NASDAQ:DERM) has received a \"Hold\" consensus recommendation from four analysts, with an average 12-month price target of $13.00. While some analysts maintain or upgraded to a \"buy\" rating, Weiss Ratings reaffirmed a \"sell.\" The company recently report", "url": "https://www.marketbeat.com/instant-alerts/journey-medical-corporation-nasdaqderm-receives-average-recommendation-of-hold-from-analysts-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T08:10:07", "published_display": "10 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp focuses on dermatology growth. DERM stock reflects a specialized niche strategy", "summary": "Journey Medical Corp (DERM) is a biopharmaceutical company specializing in prescription dermatology treatments for common skin conditions. The company's strategy focuses on a niche market, leveraging a concentrated sales infrastructure for conditions like acne and rosacea, and ai", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/journey-medical-corp-focuses-on-dermatology-growth-derm-stock-reflects-a/69715509", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:41:27", "published_display": "07 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) grants 50,000 restricted stock units to director", "summary": "Journey Medical Corp (DERM) director Toledano Miranda Jayne was granted 50,000 restricted stock units (RSUs) on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three annual installments starting July 1, 2029, and increase Toledano's direct holdings to 1", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-cea495bbf48d.html", "source_name": "Stock Titan", "published_at": "2026-07-04T02:10:23", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) grants director 50,000 restricted stock units", "summary": "Journey Medical Corp (DERM) director Neil Herskowitz was granted 50,000 restricted stock units (RSUs) on July 1, 2026, as part of his equity compensation under the company\u2019s 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031. Following this award, Hersk", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-7010bec8c541.html", "source_name": "Stock Titan", "published_at": "2026-07-03T02:10:26", "published_display": "03 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Journey Medical Corp For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing by Journey Medical Corp for July 2nd, as reported by Investing.com. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in their company's stock. The article itself ", "url": "https://uk.investing.com/news/stock-market-news/form-4-journey-medical-corp-for-2-july-93CH-4755574", "source_name": "Investing.com UK", "published_at": "2026-07-02T21:10:00", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director awarded 50,000 RSUs in long-term stock plan grant", "summary": "Journey Medical Corp director Justin Adam Smith was granted 50,000 restricted stock units (RSUs) as equity compensation on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031, aligning his compensation with future compan", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-b8ab2a33fb22.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:09:30", "published_display": "02 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Journey Medical Corp For: 26 June By Investing.com", "summary": "This article from Investing.com reports the filing of Form 4 for Journey Medical Corp on June 26th. It notes the stock symbol DERM and its performance (+4.27%). The content is very brief, mainly serving as an announcement of the filing without further details.", "url": "https://ng.investing.com/news/stock-market-news/form-4-journey-medical-corp-for-26-june-93CH-2576475", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T22:40:43", "published_display": "27 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) 2026 meeting backs all directors and re-approves KPMG", "summary": "Journey Medical Corporation held its 2026 annual stockholder meeting where 81% of eligible shares were represented, establishing a quorum. Stockholders approved the re-election of all six director nominees, each receiving over 31.7 million votes. Additionally, KPMG LLP was re-app", "url": "https://www.stocktitan.net/sec-filings/DERM/8-k-journey-medical-corp-reports-material-event-86f3c3eceb5c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:38", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director awarded 10,000 restricted stock units in equity grant", "summary": "Journey Medical Corp director Neil Herskowitz was granted 10,000 restricted stock units (RSUs) as equity compensation under the company's 2015 Stock Plan. These RSUs will vest in full on June 25, 2027, bringing Herskowitz's direct holdings to 118,618 shares, including other restr", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-7c31103135b5.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:21:20", "published_display": "26 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Journey Medical (DERM) receives 10,000 restricted stock units", "summary": "Journey Medical Corp director Justin Adam Smith was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest on June 25, 2027. This equity award, made under the company\u2019s 2015 Stock Plan, increases Smith's direct holdings to 181,618 shares, including other u", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-5610742ce375.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:21:20", "published_display": "26 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director receives 10,000 RSUs vesting in 2027", "summary": "Journey Medical Corp director Michael Cooper was granted 10,000 Restricted Stock Units (RSUs) on June 25, 2026, as per a Form 4 filing. These RSUs, awarded under the company's 2015 Stock Plan, will fully vest into 10,000 common shares on June 25, 2027. Following this grant, Coope", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-2b1c324a2feb.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:18:20", "published_display": "26 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director granted 10,000 RSUs, holds over 397K shares", "summary": "Journey Medical Corp director Lindsay A. Rosenwald, M.D. was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest entirely on June 25, 2027. Following this award, Dr. Rosenwald directly holds 221,146 shares and indirectly holds 176,470 shares through an ", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-759b865ceccb.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:16:20", "published_display": "26 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOS0drb2N0b0xKQ3F1U3BVelBTN1h3SENMSUR5Ry1pbVZKdGxEY0JiMlEzeHB5WnIyMGstbEptLXNFWUpwT0xld0lyMHdMamxCVWNDblp1ZzR2SnA4NVA1MlhnV1lSMlR3a2N0MFZCdFBoeUVpYnNLeHNNY0VzYUduUW9tMGxBeS1WaFVyU0g4QUpZN2Iyd01sOVJQclJ6QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Journey Medical Corp (DERM), noting its current valuation score of 9.11, ranking 51st in the Pharmaceuticals industry. The analysis details the company's current P/E ratio, its deviation from recent highs and lows, and mentions that ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:20", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Institutional Confidence", "summary": "Journey Medical Corp (DERM) has an institutional shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding witnessed a significant quarter-over-quarter increase of 93.34%, with the largest shareholder, Bill Nygren, holding ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Journey Medical Corp (DERM) has an earnings forecast score of 8.00, placing it well within the Pharmaceuticals industry. Analysts have set an average price target of $13.00, with a consensus \"Buy\" rating based on four analysts. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Journey Medical Corp (DERM), detailing its performance by business segments and regional contributions. As of April 6, the company's fiscal year 2025 revenue is dominated by Qbrexza, Emrosia, and Accutane. The entire revenue generated", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:15", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a financial overview of Journey Medical Corp (DERM), focusing on its dividend and stock split history. It states that the company has not distributed dividends in the past five years and has no record of stock splits. The page also displays current stock para", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOTUFmc1UtVV9tUEtvWU1Zd1lnNWh3TmVEMU5Eb0N0WkNBdWYyd0xIbjlranRrNEtFRUtsWFFvdlJMS0w4ekNieG9PaGVwMVlXU0JvRlo1NnlqamNpRklaZzZWb0VBa1VLZ3pMbm43cXhBV2xwSU03SjRpMnp5WGZzNl9sVHd3LXU2T3duR0E4bzJVYkxOcG1FRk5ISF9BNnJXM2FMa0dSSGxWZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Shares Drop\u2014DERM\u2019s 2026 Outlook Hinges on Emrosi Trial", "summary": "Journey Medical Corp's shares dropped 3.5% after no new company statement was released. The company's 2026 outlook is heavily dependent on the performance of its rosacea drug, Emrosi, specifically its ability to increase prescriptions, secure payer coverage, maintain margins, and", "url": "https://www.bez-kabli.pl/journey-medical-shares-drop-derms-2026-outlook-hinges-on-emrosi-trial/", "source_name": "Bez Kabli", "published_at": "2026-06-02T23:03:00", "published_display": "02 Jun 2026 23:03", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp stock (US48113J1007): calm start to the week after recent gains", "summary": "Journey Medical Corp (DERM) shares started the week calmly on Nasdaq after recent gains in May, maintaining its presence in the U.S. small-cap market. The commercial-stage dermatology specialist's stock traded in a mid-single-digit dollar range, attracting attention from investor", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/journey-medical-corp-stock-us48113j1007-calm-start-to-the-week-after/69465861", "source_name": "Ad Hoc News", "published_at": "2026-06-01T18:10:43", "published_display": "01 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise", "summary": "Journey Medical Corporation reported a strong first quarter for 2026, with total net product revenues increasing 21% year-over-year, driven by a 200% surge in EMROSI product revenue. The company achieved positive adjusted EBITDA of $600,000 and increased its cash position to $27.", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-journey-medical-q1-2026-shows-21-revenue-rise-93CH-4709185", "source_name": "Investing.com", "published_at": "2026-05-26T11:10:36", "published_display": "26 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Analyst Ratings and Price Targets | NASDAQ:DERM", "summary": "Journey Medical Corp (NASDAQ: DERM) has a consensus price target of $11.08 from 6 analysts, with a high of $13.00 from HC Wainwright & Co. and a low of $8.50 from Alliance Global Partners. Recent ratings suggest a potential 106.02% upside for the stock. The latest analyst rating ", "url": "https://www.benzinga.com/quote/DERM/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-24T09:10:32", "published_display": "24 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical CEO to join online talk at A.G.P. health event", "summary": "Journey Medical Corporation announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on May 20, 2026, at 5:00 p.m. ET. The company, focused on FDA-approved dermatological products, enco", "url": "https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-eipjqyjy6809.html", "source_name": "Stock Titan", "published_at": "2026-05-20T19:40:07", "published_display": "20 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical CEO to join A.G.P. Virtual Healthcare Conference fireside chat on May 20, 2026", "summary": "Journey Medical Corporation's CEO, Claude Maraoui, is scheduled to participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. The company specializes in dermatological prescription drugs and markets eight branded products. This event provides", "url": "https://pluang.com/en/news-feed/journey-medical-corporation-ikut-konferensi-virtual-kesehatan-agp", "source_name": "Pluang", "published_at": "2026-05-20T00:39:39", "published_display": "20 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "Journey Medical Corporation (Nasdaq: DERM) announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 5:00 PM ET. The company is a commercial-stage pharmace", "url": "https://www.manilatimes.net/2026/05/20/tmt-newswire/globenewswire/journey-medical-corporation-to-participate-in-agps-annual-virtual-healthcare-conference/2347709", "source_name": "The Manila Times", "published_at": "2026-05-19T20:39:39", "published_display": "19 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/76ed40f3-afce-3429-8711-ba25f5b9e48d/journey-medical-corporation.html", "source_name": "Moby", "published_at": "2026-05-15T00:25:26+00:00", "published_display": "15 May 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/journey-medical-corp-derm-q1-050139411.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:01:39+00:00", "published_display": "14 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Journey Medical Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-journey-medical-q1-2026-211722660.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:17:22+00:00", "published_display": "13 May 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (Nasdaq: DERM) posts 21% Q1 2026 revenue growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNTmtjb0FHUDFMTEwwbXdJNFlWV0lfLTM4OUhWakxVaF9xV3hocjdIM0FzUEROVXQ4TFk3MmlyZXZTS2Rkc1pJaFhobGtUNFVNTzRUYmhSaUMtYlRDczBpNzlxMXAya0xfeUVZOEowV2JIZlJjSGNIdkNVZmVPQ2liUWVINE9XQzlwOHhRWDdHa2VxMFZOa0hZejlaVXJYOXlLUE5ybjVpMnozY1Q5ckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPM1JTMjN0ZFFaR3dsTlhKT3pIX1d2aEN0aW5naFEwNHNXOXg5dGNsMDBMWnl2VnRyaWFFMEtLMkplWUtvdXRpdU9kMDk1NVVRVTRYbE5oc29VaE4wd3ZKTDdkV3FNSjhmc2pSUXBUX1pmWXRZUDhIR2JYZ1YwNTdlOHRKRzdxWXZPTXpranBXZnlzRy1V?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ2xmYnlqNGRONmozVU1CMVZxZGpvaTFwZ1ZlYS1ES2NMQzhWR0RjbVV4X0hYNWFNQkdyRnRjSURIc1dGTjFPb0ZuWE5LOTZnSUMtZjA0bDk3clNIaUpzOEtZUERuTkozN2hSMGlBbUVRYno1dE5HQ09yZVpUR19YbWptbF8zb094czZ3dUhpV3d3SGY5OGk3QVlaZEJoaDh2OWtkVmdDcWk4SUE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQcEFyb3FrbEdKMENHN3haS0FpLWFidlVSYzR2NjFYc2g5S09BVTJ5ZWRmYjdFWHNNUjBqSzVuYnZIbTE1RjhOTmVoUmtPQTNxUFQySF9KYlpVM19NdWI0bnVfM3RtR0JiQVM3SzRsSmRzR1BUb1l3NE5MZDk3TkkwRW9hdGFHTUhXbkpjYldXYUlkR1RrR2IzQTRvN0pWN1JLQ20tNlA3anZIRXZxY1E?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxQWjAzT01Sa3BnUzNTYlZRN2RjR3pKc1NuY0JKWkpkcnJWM3YzQUVlQ2gweXpJVGVLWUoxZWVPRGlfSk9rRkpOUWkzeGJYVnIxVG9xMWl4b2JMdWQzQnUwbE1oMmVtbERhM1dtQXhIQnd1a0hGZGI2Tm9qNEZ3enVhbm9WY19oVnNvVmlXN1pycFhhTTNKMmI3X2VEZ1FaamVzdWpEOUdKZjc1Zl9hQS0tdmNpU1FNNGNNR0lDd0RZRDhGWDFUMDBMcG9qVmZ2SVlhSW1UYWJ3ZGhzUS1fczgzOE45enZBSkdLMWczekhFQ05qSFJmSWp3X1pyRGhzcllmOEdSWDBndw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQUl3RTBYT2NWc0xUTXhadUNOV212UG1MRHM4YzI1ei1tVDlEZEk5azVQSUk2VXloNmRHd2pmWEt3UHB3TkdxQkZIYmlNMUloYU5PVV9RUFR0THZTX1ZxT3pSOXEwR0JrekJVVENUelpJa2YtcGI1LXZzSXZfT2R5UFNxMzNhaE0tZ09TWDU1QWVxWklrWlQ1dWNudXAxb3F6?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Losses Narrow In Q4 EPS Result Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQd0NWN0JRbXBGMmc1cU55MmwyYkRBSmc5UExHNlcyOTZPTmlTd2JhX0FZWThJVF9UbzNVR1kyajY4Wk4za3lsTkpHd2x3Y2JOYjlzNVRMVXp4UEp4RUM0MGtEc0tZY0dvWU15MGhLMndGblc4bVFhTHZrdTVhMm9fY2pQd3AtNklnZHlFOHFhZEVuZ2JZWmZpeGN1NXhRZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Q4 2025: Everything You Need To Know Ahead Of Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQNnhkRjRDTkNZWm5IcEd5elZuU29vZWE5TkdSU0RfbGpoOXd2ZTRfZkE1U0dHWXp6QWxqQWtwS3FBZDNndUVDQ3J6a0ZGMHQ0dVpBTmc2QUxFNWg1Ym82V096Q1k3TVpSR3RVZDVWeHhmb2JDZGtZTHB6S3VvNDlaM0QwNWp0dUZocUVXSXFKcTItX1gzMElZNw?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQUXZreDRieE1Xb3h4bERkc3VzWlNDZ1V6SW01dGhxRFZUTDJjdHdELVFMWHFOZ3BNYU9QLURqLWRUcVU3czhGRHQ1em95V3AwN1k0Y1lIMTItNHJGdWhHNGxhdmpldEg0ck1BTDlIN25qUUhNWGpNQnFkTF9kelpUS2gxMXVkMEJwQXRzNEVBdGxIX3JxSlpYZlFETTRySTdqZnJkZ3ItbnhSZEdkcmV4Q29nSENuYWxlblE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DERM Stock Price and Chart \u2014 NASDAQ:DERM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1EMXIteFpTM0ZzUHFzTVNLa0FpdWRxeVRnVERlOUplcnE0T21maWNac3hSMmNHTzRYZGhrZktNM2I4UWRCaHpUNkZXOEg3UmFzZlo1eVZoTUVxdmE3?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T02:22:45+00:00", "published_display": "21 Jul 2017 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0xamdJUzFwRVJkNG1fZmZsaDNLaE1rV1V1RzlvSXRpaG81XzVOaGFSQVVHZ3VMZUpHQUhuQ0lsdldHZFZNVEtPOVF2T0VzYWFFOXdaUmwyVTM4QQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-10T16:20:50+00:00", "published_display": "10 Aug 2016 16:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors", "summary": "Wasatch Advisors has increased its beneficial ownership in Journey Medical Corp (DERM) to 13.3%, holding 2,858,930 shares. This information was disclosed in an Amendment No. 3 to a Schedule 13G filing. Wasatch Advisors maintains sole voting power over 2,664,647 shares and sole di", "url": "https://www.stocktitan.net/sec-filings/DERM/schedule-13g-a-journey-medical-corp-amended-passive-investment-disclo-f5e09ec5230d.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:09:30", "published_display": "15 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Journey Medical Corporation \u2013 NASDAQ:DERM", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOWmlMOW14NHpUb0hBUVZfNUF0ajk1c3IzX3hsSVFib19UUDI4dVVBMlRROVdDcnR0UER3aUp5YzdkaWI2VmZUWWFsSFF0VDhJeUVMek5tenJjYS1UR0NtVXJMOUNIN1JGLXhRLXhGMkYxV2cxTXlkeDVjSHpYeUFtUjl4S1JmSWJlM1Q5MDYtaUp1dXVfUFB3amNZVkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T10:04:01+00:00", "published_display": "12 Jul 2026 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation (NASDAQ:DERM) Receives Average Recommendation of \"Hold\" from Analysts", "summary": "Journey Medical Corporation (NASDAQ:DERM) has received a \"Hold\" consensus recommendation from four analysts, with an average 12-month price target of $13.00. While some analysts maintain or upgraded to a \"buy\" rating, Weiss Ratings reaffirmed a \"sell.\" The company recently report", "url": "https://www.marketbeat.com/instant-alerts/journey-medical-corporation-nasdaqderm-receives-average-recommendation-of-hold-from-analysts-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T08:10:07", "published_display": "10 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp focuses on dermatology growth. DERM stock reflects a specialized niche strategy", "summary": "Journey Medical Corp (DERM) is a biopharmaceutical company specializing in prescription dermatology treatments for common skin conditions. The company's strategy focuses on a niche market, leveraging a concentrated sales infrastructure for conditions like acne and rosacea, and ai", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/journey-medical-corp-focuses-on-dermatology-growth-derm-stock-reflects-a/69715509", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:41:27", "published_display": "07 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) grants 50,000 restricted stock units to director", "summary": "Journey Medical Corp (DERM) director Toledano Miranda Jayne was granted 50,000 restricted stock units (RSUs) on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three annual installments starting July 1, 2029, and increase Toledano's direct holdings to 1", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-cea495bbf48d.html", "source_name": "Stock Titan", "published_at": "2026-07-04T02:10:23", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) grants director 50,000 restricted stock units", "summary": "Journey Medical Corp (DERM) director Neil Herskowitz was granted 50,000 restricted stock units (RSUs) on July 1, 2026, as part of his equity compensation under the company\u2019s 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031. Following this award, Hersk", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-7010bec8c541.html", "source_name": "Stock Titan", "published_at": "2026-07-03T02:10:26", "published_display": "03 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Journey Medical Corp For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing by Journey Medical Corp for July 2nd, as reported by Investing.com. A Form 4 is a document filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report transactions in their company's stock. The article itself ", "url": "https://uk.investing.com/news/stock-market-news/form-4-journey-medical-corp-for-2-july-93CH-4755574", "source_name": "Investing.com UK", "published_at": "2026-07-02T21:10:00", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director awarded 50,000 RSUs in long-term stock plan grant", "summary": "Journey Medical Corp director Justin Adam Smith was granted 50,000 restricted stock units (RSUs) as equity compensation on July 1, 2026, under the company's 2015 Stock Plan. These RSUs will vest in three tranches between 2029 and 2031, aligning his compensation with future compan", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-b8ab2a33fb22.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:09:30", "published_display": "02 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Journey Medical Corp For: 26 June By Investing.com", "summary": "This article from Investing.com reports the filing of Form 4 for Journey Medical Corp on June 26th. It notes the stock symbol DERM and its performance (+4.27%). The content is very brief, mainly serving as an announcement of the filing without further details.", "url": "https://ng.investing.com/news/stock-market-news/form-4-journey-medical-corp-for-26-june-93CH-2576475", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T22:40:43", "published_display": "27 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) 2026 meeting backs all directors and re-approves KPMG", "summary": "Journey Medical Corporation held its 2026 annual stockholder meeting where 81% of eligible shares were represented, establishing a quorum. Stockholders approved the re-election of all six director nominees, each receiving over 31.7 million votes. Additionally, KPMG LLP was re-app", "url": "https://www.stocktitan.net/sec-filings/DERM/8-k-journey-medical-corp-reports-material-event-86f3c3eceb5c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:40:38", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director awarded 10,000 restricted stock units in equity grant", "summary": "Journey Medical Corp director Neil Herskowitz was granted 10,000 restricted stock units (RSUs) as equity compensation under the company's 2015 Stock Plan. These RSUs will vest in full on June 25, 2027, bringing Herskowitz's direct holdings to 118,618 shares, including other restr", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-7c31103135b5.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:21:20", "published_display": "26 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Journey Medical (DERM) receives 10,000 restricted stock units", "summary": "Journey Medical Corp director Justin Adam Smith was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest on June 25, 2027. This equity award, made under the company\u2019s 2015 Stock Plan, increases Smith's direct holdings to 181,618 shares, including other u", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-5610742ce375.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:21:20", "published_display": "26 Jun 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director receives 10,000 RSUs vesting in 2027", "summary": "Journey Medical Corp director Michael Cooper was granted 10,000 Restricted Stock Units (RSUs) on June 25, 2026, as per a Form 4 filing. These RSUs, awarded under the company's 2015 Stock Plan, will fully vest into 10,000 common shares on June 25, 2027. Following this grant, Coope", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-2b1c324a2feb.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:18:20", "published_display": "26 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) director granted 10,000 RSUs, holds over 397K shares", "summary": "Journey Medical Corp director Lindsay A. Rosenwald, M.D. was granted 10,000 restricted stock units (RSUs) on June 25, 2026, which will vest entirely on June 25, 2027. Following this award, Dr. Rosenwald directly holds 221,146 shares and indirectly holds 176,470 shares through an ", "url": "https://www.stocktitan.net/sec-filings/DERM/form-4-journey-medical-corp-insider-trading-activity-759b865ceccb.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:16:20", "published_display": "26 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOS0drb2N0b0xKQ3F1U3BVelBTN1h3SENMSUR5Ry1pbVZKdGxEY0JiMlEzeHB5WnIyMGstbEptLXNFWUpwT0xld0lyMHdMamxCVWNDblp1ZzR2SnA4NVA1MlhnV1lSMlR3a2N0MFZCdFBoeUVpYnNLeHNNY0VzYUduUW9tMGxBeS1WaFVyU0g4QUpZN2Iyd01sOVJQclJ6QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Journey Medical Corp (DERM), noting its current valuation score of 9.11, ranking 51st in the Pharmaceuticals industry. The analysis details the company's current P/E ratio, its deviation from recent highs and lows, and mentions that ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T06:39:20", "published_display": "18 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Institutional Confidence", "summary": "Journey Medical Corp (DERM) has an institutional shareholding score of 5.00, placing it 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding witnessed a significant quarter-over-quarter increase of 93.34%, with the largest shareholder, Bill Nygren, holding ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Journey Medical Corp (DERM) has an earnings forecast score of 8.00, placing it well within the Pharmaceuticals industry. Analysts have set an average price target of $13.00, with a consensus \"Buy\" rating based on four analysts. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Journey Medical Corp (DERM), detailing its performance by business segments and regional contributions. As of April 6, the company's fiscal year 2025 revenue is dominated by Qbrexza, Emrosia, and Accutane. The entire revenue generated", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:15", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides a financial overview of Journey Medical Corp (DERM), focusing on its dividend and stock split history. It states that the company has not distributed dividends in the past five years and has no record of stock splits. The page also displays current stock para", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-derm/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:14", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOTUFmc1UtVV9tUEtvWU1Zd1lnNWh3TmVEMU5Eb0N0WkNBdWYyd0xIbjlranRrNEtFRUtsWFFvdlJMS0w4ekNieG9PaGVwMVlXU0JvRlo1NnlqamNpRklaZzZWb0VBa1VLZ3pMbm43cXhBV2xwSU03SjRpMnp5WGZzNl9sVHd3LXU2T3duR0E4bzJVYkxOcG1FRk5ISF9BNnJXM2FMa0dSSGxWZw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Shares Drop\u2014DERM\u2019s 2026 Outlook Hinges on Emrosi Trial", "summary": "Journey Medical Corp's shares dropped 3.5% after no new company statement was released. The company's 2026 outlook is heavily dependent on the performance of its rosacea drug, Emrosi, specifically its ability to increase prescriptions, secure payer coverage, maintain margins, and", "url": "https://www.bez-kabli.pl/journey-medical-shares-drop-derms-2026-outlook-hinges-on-emrosi-trial/", "source_name": "Bez Kabli", "published_at": "2026-06-02T23:03:00", "published_display": "02 Jun 2026 23:03", "sentiment": "negative", "sentiment_pct": 38, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp stock (US48113J1007): calm start to the week after recent gains", "summary": "Journey Medical Corp (DERM) shares started the week calmly on Nasdaq after recent gains in May, maintaining its presence in the U.S. small-cap market. The commercial-stage dermatology specialist's stock traded in a mid-single-digit dollar range, attracting attention from investor", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/journey-medical-corp-stock-us48113j1007-calm-start-to-the-week-after/69465861", "source_name": "Ad Hoc News", "published_at": "2026-06-01T18:10:43", "published_display": "01 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise", "summary": "Journey Medical Corporation reported a strong first quarter for 2026, with total net product revenues increasing 21% year-over-year, driven by a 200% surge in EMROSI product revenue. The company achieved positive adjusted EBITDA of $600,000 and increased its cash position to $27.", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-journey-medical-q1-2026-shows-21-revenue-rise-93CH-4709185", "source_name": "Investing.com", "published_at": "2026-05-26T11:10:36", "published_display": "26 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Analyst Ratings and Price Targets | NASDAQ:DERM", "summary": "Journey Medical Corp (NASDAQ: DERM) has a consensus price target of $11.08 from 6 analysts, with a high of $13.00 from HC Wainwright & Co. and a low of $8.50 from Alliance Global Partners. Recent ratings suggest a potential 106.02% upside for the stock. The latest analyst rating ", "url": "https://www.benzinga.com/quote/DERM/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-24T09:10:32", "published_display": "24 May 2026 09:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical CEO to join online talk at A.G.P. health event", "summary": "Journey Medical Corporation announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on May 20, 2026, at 5:00 p.m. ET. The company, focused on FDA-approved dermatological products, enco", "url": "https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-eipjqyjy6809.html", "source_name": "Stock Titan", "published_at": "2026-05-20T19:40:07", "published_display": "20 May 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical CEO to join A.G.P. Virtual Healthcare Conference fireside chat on May 20, 2026", "summary": "Journey Medical Corporation's CEO, Claude Maraoui, is scheduled to participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference on May 20, 2026. The company specializes in dermatological prescription drugs and markets eight branded products. This event provides", "url": "https://pluang.com/en/news-feed/journey-medical-corporation-ikut-konferensi-virtual-kesehatan-agp", "source_name": "Pluang", "published_at": "2026-05-20T00:39:39", "published_display": "20 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation to Participate in A.G.P.\u2019s Annual Virtual Healthcare Conference", "summary": "Journey Medical Corporation (Nasdaq: DERM) announced that its Co-Founder, President, and CEO, Claude Maraoui, will participate in a fireside chat at A.G.P.\u2019s Annual Virtual Healthcare Conference on Wednesday, May 20, 2026, at 5:00 PM ET. The company is a commercial-stage pharmace", "url": "https://www.manilatimes.net/2026/05/20/tmt-newswire/globenewswire/journey-medical-corporation-to-participate-in-agps-annual-virtual-healthcare-conference/2347709", "source_name": "The Manila Times", "published_at": "2026-05-19T20:39:39", "published_display": "19 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/76ed40f3-afce-3429-8711-ba25f5b9e48d/journey-medical-corporation.html", "source_name": "Moby", "published_at": "2026-05-15T00:25:26+00:00", "published_display": "15 May 2026 00:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/journey-medical-corp-derm-q1-050139411.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T05:01:39+00:00", "published_display": "14 May 2026 05:01", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript: Journey Medical Q1 2026 Earnings Conference Call", "summary": "", "url": "https://finance.yahoo.com/news/transcript-journey-medical-q1-2026-211722660.html", "source_name": "Benzinga", "published_at": "2026-05-13T21:17:22+00:00", "published_display": "13 May 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (Nasdaq: DERM) posts 21% Q1 2026 revenue growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNTmtjb0FHUDFMTEwwbXdJNFlWV0lfLTM4OUhWakxVaF9xV3hocjdIM0FzUEROVXQ4TFk3MmlyZXZTS2Rkc1pJaFhobGtUNFVNTzRUYmhSaUMtYlRDczBpNzlxMXAya0xfeUVZOEowV2JIZlJjSGNIdkNVZmVPQ2liUWVINE9XQzlwOHhRWDdHa2VxMFZOa0hZejlaVXJYOXlLUE5ybjVpMnozY1Q5ckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPM1JTMjN0ZFFaR3dsTlhKT3pIX1d2aEN0aW5naFEwNHNXOXg5dGNsMDBMWnl2VnRyaWFFMEtLMkplWUtvdXRpdU9kMDk1NVVRVTRYbE5oc29VaE4wd3ZKTDdkV3FNSjhmc2pSUXBUX1pmWXRZUDhIR2JYZ1YwNTdlOHRKRzdxWXZPTXpranBXZnlzRy1V?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Q1 2026 Earnings Transcript", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ2xmYnlqNGRONmozVU1CMVZxZGpvaTFwZ1ZlYS1ES2NMQzhWR0RjbVV4X0hYNWFNQkdyRnRjSURIc1dGTjFPb0ZuWE5LOTZnSUMtZjA0bDk3clNIaUpzOEtZUERuTkozN2hSMGlBbUVRYno1dE5HQ09yZVpUR19YbWptbF8zb094czZ3dUhpV3d3SGY5OGk3QVlaZEJoaDh2OWtkVmdDcWk4SUE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQcEFyb3FrbEdKMENHN3haS0FpLWFidlVSYzR2NjFYc2g5S09BVTJ5ZWRmYjdFWHNNUjBqSzVuYnZIbTE1RjhOTmVoUmtPQTNxUFQySF9KYlpVM19NdWI0bnVfM3RtR0JiQVM3SzRsSmRzR1BUb1l3NE5MZDk3TkkwRW9hdGFHTUhXbkpjYldXYUlkR1RrR2IzQTRvN0pWN1JLQ20tNlA3anZIRXZxY1E?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxQWjAzT01Sa3BnUzNTYlZRN2RjR3pKc1NuY0JKWkpkcnJWM3YzQUVlQ2gweXpJVGVLWUoxZWVPRGlfSk9rRkpOUWkzeGJYVnIxVG9xMWl4b2JMdWQzQnUwbE1oMmVtbERhM1dtQXhIQnd1a0hGZGI2Tm9qNEZ3enVhbm9WY19oVnNvVmlXN1pycFhhTTNKMmI3X2VEZ1FaamVzdWpEOUdKZjc1Zl9hQS0tdmNpU1FNNGNNR0lDd0RZRDhGWDFUMDBMcG9qVmZ2SVlhSW1UYWJ3ZGhzUS1fczgzOE45enZBSkdLMWczekhFQ05qSFJmSWp3X1pyRGhzcllmOEdSWDBndw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQUl3RTBYT2NWc0xUTXhadUNOV212UG1MRHM4YzI1ei1tVDlEZEk5azVQSUk2VXloNmRHd2pmWEt3UHB3TkdxQkZIYmlNMUloYU5PVV9RUFR0THZTX1ZxT3pSOXEwR0JrekJVVENUelpJa2YtcGI1LXZzSXZfT2R5UFNxMzNhaE0tZ09TWDU1QWVxWklrWlQ1dWNudXAxb3F6?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Losses Narrow In Q4 EPS Result Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQd0NWN0JRbXBGMmc1cU55MmwyYkRBSmc5UExHNlcyOTZPTmlTd2JhX0FZWThJVF9UbzNVR1kyajY4Wk4za3lsTkpHd2x3Y2JOYjlzNVRMVXp4UEp4RUM0MGtEc0tZY0dvWU15MGhLMndGblc4bVFhTHZrdTVhMm9fY2pQd3AtNklnZHlFOHFhZEVuZ2JZWmZpeGN1NXhRZw?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical Corp (DERM) Q4 2025: Everything You Need To Know Ahead Of Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQNnhkRjRDTkNZWm5IcEd5elZuU29vZWE5TkdSU0RfbGpoOXd2ZTRfZkE1U0dHWXp6QWxqQWtwS3FBZDNndUVDQ3J6a0ZGMHQ0dVpBTmc2QUxFNWg1Ym82V096Q1k3TVpSR3RVZDVWeHhmb2JDZGtZTHB6S3VvNDlaM0QwNWp0dUZocUVXSXFKcTItX1gzMElZNw?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQUXZreDRieE1Xb3h4bERkc3VzWlNDZ1V6SW01dGhxRFZUTDJjdHdELVFMWHFOZ3BNYU9QLURqLWRUcVU3czhGRHQ1em95V3AwN1k0Y1lIMTItNHJGdWhHNGxhdmpldEg0ck1BTDlIN25qUUhNWGpNQnFkTF9kelpUS2gxMXVkMEJwQXRzNEVBdGxIX3JxSlpYZlFETTRySTdqZnJkZ3ItbnhSZEdkcmV4Q29nSENuYWxlblE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DERM Stock Price and Chart \u2014 NASDAQ:DERM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1EMXIteFpTM0ZzUHFzTVNLa0FpdWRxeVRnVERlOUplcnE0T21maWNac3hSMmNHTzRYZGhrZktNM2I4UWRCaHpUNkZXOEg3UmFzZlo1eVZoTUVxdmE3?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T02:22:45+00:00", "published_display": "21 Jul 2017 02:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Journey Medical (DERM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0xamdJUzFwRVJkNG1fZmZsaDNLaE1rV1V1RzlvSXRpaG81XzVOaGFSQVVHZ3VMZUpHQUhuQ0lsdldHZFZNVEtPOVF2T0VzYWFFOXdaUmwyVTM4QQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-10T16:20:50+00:00", "published_display": "10 Aug 2016 16:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 71, "total_relevant": 43, "sentiment_summary": {"positive": 8, "negative": 2, "neutral": 33, "score": 53, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 6.91, "latest_week": "2026-07-10", "one_week_move": -2.5, "four_week_move": 9.0, "twelve_week_move": 28.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.762719, "market_dynamics_buy_signal": false, "relative_strength": -16.824738, "fair_value_gap": 24.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 54.8951, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.5% over one week, +9.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "TradingView", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Benzinga", "count": 2}, {"label": "AD HOC NEWS", "count": 1}, {"label": "Investing.com UK", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 4}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.5% over one week, +9.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Journey Medical (DERM) gains 13.3% shareholder in Wasatch Advisors"}], "updated_at": "2026-07-16T18:58:17.128085+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}